Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kymera Therapeutics ( (KYMR) ) has issued an update.
On June 25, 2025, Kymera Therapeutics announced an exclusive option and license agreement with Gilead Sciences to develop novel oral molecular glue CDK2 degraders for oncology treatment, including breast cancer. The agreement could bring Kymera up to $750 million in payments and royalties, with Kymera leading research activities. This collaboration aims to advance cancer treatment by selectively targeting and degrading disease-driving proteins, potentially improving care for patients with high unmet medical needs.
The most recent analyst rating on (KYMR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.
Spark’s Take on KYMR Stock
According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.
Kymera Therapeutics’ overall stock score reflects a mix of strong technical indicators and promising corporate developments, tempered by financial challenges. The company’s robust pipeline and strategic focus on high-value programs enhance its future potential, despite current profitability issues.
To see Spark’s full report on KYMR stock, click here.
More about Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems. The company focuses on building an industry-leading pipeline of oral small molecule degraders to provide new, effective therapies for conditions that are inadequately addressed by existing technologies.
Average Trading Volume: 878,798
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.01B
See more data about KYMR stock on TipRanks’ Stock Analysis page.